Holen Sie sich die Stockscreener-App
14.33
2.38%
-0.35
Vorhandelsmarkt:
14.48
0.15
+1.05%
Schlusskurs vom Vortag:
$14.68
Offen:
$14.58
24-Stunden-Volumen:
616.12K
Relative Volume:
0.82
Marktkapitalisierung:
$1.21B
Einnahmen:
$568.09M
Nettoeinkommen (Verlust:
$27.27M
KGV:
43.74
EPS:
0.3276
Netto-Cashflow:
$71.41M
1W Leistung:
+3.17%
1M Leistung:
+23.75%
6M Leistung:
+67.02%
1J Leistung:
+98.75%
1-Tages-Spanne:
$14.20
$14.75
1-Wochen-Bereich:
$13.64
$14.92
52-Wochen-Spanne:
$6.255
$15.89
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
14.33 | 1.23B | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | CJS Securities | Market Outperform |
| 2026-02-09 | Eingeleitet | Barrington Research | Outperform |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Can Bioventus (NASDAQ:BVS) Keep Its Momentum Going? - Kalkine Media
BVS Maintains Buy Rating by Canaccord Genuity -- Price Target Ra - GuruFocus
BVS Reiterated by Cantor Fitzgerald -- Price Target Maintained a - GuruFocus
Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
CCORF Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $19 - Moomoo
Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
(BVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Dimensional Fund Advisors LP Increases Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance
Theravance Bio: Q2 Earnings Snapshot - AOL.com
Bioventus (NASDAQ:BVS) Gains Attention After Strong Quarterly Update - Kalkine Media
Sei Investments Co. Boosts Holdings in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - Sahm
Bioventus Inc. (BVS) Stock Analysis: Healthcare Innovator With 5.87% Upside Potential - DirectorsTalk Interviews
Bioventus Inc (BVS) Stock News Today - TradingKey
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Bioventus Inc. $BVS Shares Sold by Renaissance Technologies LLC - MarketBeat
Latham & Watkins Advises Bioventus in Review of Strategic Alternatives - Latham & Watkins LLP
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Bioventus Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain - simplywall.st
Bioventus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Bioventus Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-08-05 - Seeking Alpha
Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ... - Yahoo Finance
Earnings call transcript: Bioventus posts Q2 2026 EPS beat, shares slip premarket - Investing.com Nigeria
Bioventus (NASDAQ:BVS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bioventus Inc. Q2 2026 Earnings: Strong Revenue Growth, Net Income, and Financial Highlights - Minichart
Bioventus Inc. Reports Q2 2026 Results and Strategic Review in Latest 10-Q Filing - Kalkine Media
Bioventus Q2 Earnings Call Highlights - MarketBeat
Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed - marketscreener.com
Bioventus Reaffirms Earnings Guidance for the Twelve Months Ending December 31, 2026 - marketscreener.com
Bioventus Stock (BVS) Opinions on Strategic Review Announcement - Quiver Quantitative
Transcript : Bioventus Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Bioventus Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Bioventus (NASDAQ:BVS) Releases FY 2026 Earnings Guidance - MarketBeat
Bioventus Q2 2026 Earnings Call Transcript - MarketBeat
Bioventus (BVS) Q2 Earnings Meet Estimates - Yahoo Finance
(BVS) Bioventus Expects 2026 Adjusted EPS Range $0.75$0.79, vs. FactSet Est of $0.78 - marketscreener.com
(BVS) Bioventus Expects Full Year 2026 Revenue Range 600M-$610M, vs. FactSet Est of $605.3M - marketscreener.com
Earnings Flash (BVS) Bioventus Inc. Reports Q2 Revenue $153.2M, vs. FactSet Est of $155.4M - marketscreener.com
Earnings Flash (BVS) Bioventus Inc. Posts Q2 Adjusted EPS $0.22 per Share, vs. FactSet Est of $0.22 - marketscreener.com
Bioventus Inc. 2026: Revenue $153.21M, EPS $0.47— 10-Q Summary - TradingView
Bioventus Q2 Revenue Rises 4% as Strategic Review Begins - Quiver Quantitative
Bioventus Reports Q2 2026 Revenue Growth and Initiates Review of Strategic Alternatives - Quiver Quantitative
Bioventus Q2 revenue misses estimates on surgical solutions decline - TradingView
Bioventus Reports Second Quarter Financial Results - The Manila Times
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):